IDH2 and glioblastoma: Fortunately, this key issue has been at least indirectly investigated in a recent study by Han et al. [29], where the authors could not demonstrate any relationship between the levels of serum Alb and the incidences of MGMT promoter methylation and the IDH1-R132H mutation status which accounts for nearly 90% of all IDH mutations in GBM.